Zymeworks BC Inc(ZYME) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:42 PM ET (Korea 10/30 05:42)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.01 | Insider Own | 3.66% | Shs Outstand | 71.4M | Perf Week | 0.95% |
| Market Cap | 2.04B | Forward P/E | 21.68 | EPS next Y | 11.43% | Insider Trans | -0.53% | Shs Float | 68.9M | Perf Month | 8.38% |
| Enterprise Value | 2.04B | PEG | - | EPS next Q | 2.27 | Inst Own | 99.46% | Short Float | 8.1% | Perf Quarter | 30.86% |
| Income | -0.15B | P/S | 54.92 | EPS this Y | 210.05% | Inst Trans | -3.71% | Short Ratio | 6.18 | Perf Half Y | 4.25% |
| Sales | 0.04B | P/B | 25.71 | EPS next 5Y | - | ROA | -37.25% | Short Interest | 5.58M | Perf YTD | 9.04% |
| Book/sh | 1.12 | P/C | 7.53 | EPS past 3/5Y | - 21.35% | ROE | -72.31% | 52W High | -8.39% ($31.34) | Perf Year | 48.14% |
| Cash/sh | 3.81 | P/FCF | - | Sales past 3/5Y | -36.43% 22.16% | ROIC | -43.39% | 52W Low | 79.4% ($16.00) | Perf 3Y | 331.73% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -106.07% | Gross Margin | 75.55% | Volatility(W/M) | 4.04% 4.17% | Perf 5Y | 29.03% |
| Dividend TTM | - | EV/Sales | 54.86 | Sales Y/Y TTM | -69.78% | Oper. Margin | -418.99% | ATR (14) | 1.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.32 | EPS Q/Q | -2162.88% | Profit Margin | -404% | RSI (14) | 61.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.32 | Sales Q/Q | -90.58% | SMA20 | 7.81% ($26.63) | Beta | 1.33 | Target Price | $41.5 |
| Payout | - | Debt/Eq | 3.34 | Earnings | 2026/11/9 | SMA50 | 5.32% ($27.26) | Rel Volume | 0.89 | Prev Close | $28.9 |
| Employees | 264 | LT Debt/Eq | 3.3 | EPS/Sales Surpr. | -7.88% 1.15% | SMA200 | 13.92% ($25.2) | Avg Volume(3M) | 0.90M | Price | $28.71 |
| IPO | 2017/4/28 | Option/Short | Yes/Yes | Trades | 7349 | Volume | 805,472 | Change | -0.66% |
🧬 This is a biotech company developing next-generation antibody-based cancer therapies. Using advanced antibody platforms such as bispecific antibodies and antibody-drug conjugates (ADCs), the company is developing treatments that target a wide range of solid tumors, and operates on a business model that combines partnerships with royalty revenue. With its differentiated antibody platforms and global collaborations, it has established itself as a cancer-focused biotech company.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
Next earnings report: November 9
10 days to go.
ZYME has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +210.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,492. Peers typically go for $1,217. Compared with its own 1-year average, it is 16% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +29.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 99.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #102 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is ZYME?
ZYME belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ZYME?
The market cap of ZYME is approximately $2.0B, ranking 2,050 within its sector.
What is the 52-week high and low for ZYME?
ZYME has recorded a 52-week high of $31.34 and a low of $16.00.
